Principal Securities’s Verona Pharma VRNA Stock Holding History

Principal Securities’s Portfolio VRNA Stock Details VRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-7	Closed	-$747	–	3453
2025 Q3	$747	Sell	7 -16	-70%	-$1.67K	﹤0.01%	3467
2025 Q2	$2.17K	Sell	23 -17	-43%	-$1.26K	﹤0.01%	3118
2025 Q1	$1.86K	Hold	40	–	–	﹤0.01%	3067
2024 Q4	$1.86K	Sell	40 -8	-17%	-$300	﹤0.01%	3061
2024 Q3	$1.38K	Buy	48 +22	+85%	+$541	﹤0.01%	3058
2024 Q2	$376	Hold	26	–	–	﹤0.01%	3241
2024 Q1	$418	Hold	26	–	–	﹤0.01%	3167
2023 Q4	$517	Buy	+26	New	+$384	﹤0.01%	3053

Other funds holding VRNA

DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return

Principal Securities's VRNA Position: Q4 2025 in Review

Principal Securities sold out of Verona Pharma (VRNA) in Q4 2025, closing a stake of 7 shares — an estimated $747 sold.

Principal Securities first reported a position in VRNA in Q4 2023 and held it in 8 quarters. The position peaked at $2.17K in Q2 2025. 1 fund tracked by Wall St. Rank holds VRNA as of Q4 2025.

Principal Securities reported no remaining Verona Pharma position as of Q4 2025 after selling out during the quarter.
Principal Securities sold 7 Verona Pharma shares in Q4 2025, an estimated $747.
Principal Securities first reported a position in Verona Pharma in Q4 2023 and held it in 8 quarters.
Principal Securities's Verona Pharma position peaked at $2.17K in Q2 2025.
1 fund tracked by Wall St. Rank held Verona Pharma as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.